S chwannomaS are tumors of the peripheral nerve sheath that usually occur singly in otherwise healthy individuals (sporadic or solitary schwannomas). They usually occur as slowly growing solitary masses in middle-aged patients without any sex predilection. Multiple schwannomas in the same individual suggest an underlying tumor predisposition syndrome. The most common example is NF2, characterized by the presence of bilateral vestibular nerve schwannomas. 9, 14, 15 In the last 15 years there have been several reports of individuals with multiple schwannomas who did not show evidence of a vestibular tumor. Based on these reports, schwannomatosis has been considered a clinical entity different from other forms of neurofibromatosis since 1996, and after several changes the current working clinical criteria were proposed (Table 1) . 3, 12, 15, 17 According to MacCollin and colleagues, 16, 19 patients meeting the criteria for definitive or possible schwannomatosis can be classified into 2 groups: FS, when an individual meeting the criteria for schwannomatosis has a first-degree relative with 1 or more schwannomas; and SS, when no other member of the family is affected.
The same authors also defined segmental schwannomatosis as a specific type of either the familial or sporadic forms, in which tumors are localized in an anatomically limited distribution (usually a single limb or contiguous segments of the spine).
group of patients with schwannomas surgically treated by a single surgeon (M.T.B.) with expertise in peripheral nerve surgery, and to identify among that group those patients with schwannomatosis in its different forms. Our objective was to provide some disease-specific information to neurologists and neurosurgeons to assist them in clinical decision making and patient and family counseling in the context of schwannomatosis. We also present the first 2 probands in the same family with a malignant schwannoma in the context of FS.
We obtained approval for this study from the Human Research and Ethics Committees of the participating institutions. The Sydney Neuro-Oncology Group and the Department of Neurosurgery, Royal North Shore Private Hospital databases were searched using diagnostic reference group codes to identify all patients in whom a diagnosis of schwannoma had been made between October 1993 and June 2008.
In each case we retrospectively analyzed patient sex and age, number of operations and tumors excised, symptoms, location and size of tumors, extent of resection, nerve function pre-and postoperatively, complications, other nonsurgically treated tumors, malignancy, results of brain MR imaging, and follow-up data. Among patients with pathologically defined schwannomas, we specifically analyzed those meeting the criteria for definite or possible schwannomatosis in its sporadic and familial forms. Clinical and demographic data on patient's family members affected by FS were included and analyzed in this report as well.
Results
Between October 1, 1993, and June 15, 2008, 158 patients underwent 180 operations for the excision of 216 schwannomas. The tumors were localized as shown in Table 2 . One hundred forty-two patients presented with solitary schwannomas, whereas 14 presented with diagnostic criteria for schwannomatosis and 2 individuals had NF2. The average follow-up was 52 months (range 6-174 months).
Schwannomatosis
Fourteen patients met the criteria for schwannomatosis: 2 for possible schwannomatosis and the other 12 for definite schwannomatosis. The average age among these patients was 28.3 years at the time of disease onset (median 27.5 years, range 10-55 years) and 35.4 years at the time of the first operation (median 37 years, range 11-62 years). Six individuals had the sporadic form of the disease, whereas 8 had at least 1 first-degree relative affected by schwannomatosis ( Table 3 ). None of them had a history of meningioma, ependymoma, or glioma. Among these 14 patients, 6 presented with SS (in its segmental form in 4) and 8 with FS (from 4 different families).
Sporadic Schwannomatosis
Six patients, 3 men and 3 women, met the criteria for SS, and 4 of them had the segmental form of the disease. Two patients met the criteria for possible schwannomatosis, and the other 4 met the diagnostic criteria for definite schwannomatosis. The average age among these patients was 31 years at the time of disease onset (median 34 years, range 10-51 years) and 40 years at the time of the first operation (median 45.5 years, range 11-62 years). These 6 patients underwent 9 operations for the resection of 31 tumors at our center plus 5 operations for the removal of 9 tumors at other centers, totaling 14 operations for the excision of 40 lesions localized as shown in Table  3 (Cases 1-6). The diameter of the tumors was between 0.5 and 2 cm. Five individuals had uncomplicated macroscopically completed tumor excision, whereas 1 patient (Case 5) experienced anesthesia dolorosa after subtotal resection of a trigeminal nerve schwannoma as well as a transitory CSF leak. New lesions developed in 2 patients during the follow-up.
All 6 patients had high-resolution (1.5-T) Gd-enhanced MR imaging excluding involvement of the vestibular nerves, and none of them had symptoms suggesting compromise of that nerve. The average follow-up of patients with SS was 64.7 months (median 66 months, range 12-144 months).
Familial Schwannomatosis
The summary data of patients with FS is shown in Table 4 (Cases 7-14). All 8 patients met the criteria for definite schwannomatosis. These 5 men and 3 women had an average age of 25.1 years (median 22 years, range 16-46 years) at the time of symptom onset and 30 years (median 27.5 years, range 17-55 years) at the time of the first operation. They presented with 61 tumors in total. They underwent 17 operations for the resection of 32 tumors at our center plus 8 operations for the removal of 11 tumors at other centers, totaling 25 operations for the excision of 43 lesions. The most common symptom on presentation was pain (all 8 patients), and the most common location of surgically treated tumors was the spine. The interval between symptom onset and the development of a mass or spinal cord compression requiring surgery ranged from a few weeks to 12 years.
The size of the surgically treated tumors ranged from 0.5 to 5.5 cm for the benign schwannomas, whereas 1 of the malignant tumors was 1 cm and the other was over 15 cm in diameter.
Among the 32 tumors excised at our center, the resection was macroscopically complete, and the functionality of nerves affected by the tumors was unchanged or improved during follow-up in 30 cases. One patient, who underwent an emergency excision of 4 schwannomas in the cauda equina causing cauda equina syndrome, recovered motor function in the lower limbs but continued to have a neurogenic bladder. The other patient had a malignant schwannoma removed from the sciatic nerve, and complete common peroneal nerve palsy developed and did not resolve. Histopathology revealed 30 schwannomas and 2 malignant schwannomas. Seven of the 8 patients had other conservatively managed tumors (18 total), and the spine was the most common location for these tumors (6 patients had at least 1 spinal tumor).
All patients had high-resolution (1.5-T) Gd-enhanced MR imaging excluding involvement of the vestibular nerves.
The pedigrees of the families studied in this report are presented in Fig. 1 .
The average follow-up of patients with FS was 57.9 months (median 57 months, range 16-102 months). New lesions developed in 2 patients during the follow-up, and 1 of them corresponded to a malignant intercostal tumor disseminated to the lungs.
In the 4 families affected by FS, 7 members over the age of 30 years were affected by schwannomatosis not treated by our team. Five of them presented with at least 1 spinal schwannoma (Table 4) .
Neurofibromatosis Type 2
The 2 individuals with NF2 underwent 9 operations for the excision of 11 tumors.
Discussion
Schwannomas are common benign tumors of the peripheral nerve that occur, in their solitary form, in genetically normal individuals. 12 Less commonly they appear as a syndrome characterized by the presence of multiple schwannomas with no diagnostic criteria for NF2, known as "schwannomatosis." 16 In 1996 MacCollin et al. 17 suggested that schwannomatosis should be considered a clinical entity different from other forms of neurofibromatosis, and in 1997 they published the first proposed diagnostic criteria for this disease. 12 These criteria were reviewed in a consensus meeting sponsored by the National Neurofibromatosis Foundation in 2005, and the current working clinical criteria were proposed. 15 In 2006 Baser et al. 3 increased the specificity of those criteria by adding the condition that all patients with definitive or possible schwannomatosis must not fulfill any of the existing sets of diagnostic criteria for NF2 and must have no evidence of vestibular schwannomas on high-quality MR imaging, no first-degree relative with NF2, and no known constitutional NF2 mutation.
In the absence of classic NF2, schwannomatosis occurs in 2%-4% of patients with schwannomas, with an annual incidence estimated at 0.58 cases/1,000,000 persons. 1, 9, 15 Familial schwannoma is present in fewer than 20% of patients with schwannomatosis. 1, 3, 5, 17 Interestingly, in the present series 9% of the patients had schwannomatosis and more than 50% of them suffered from FS, probably related to the fact that a high proportion of patients with schwannomatosis in Australia are treated at the participating institutions. Another possible bias in our series is the low proportion of patients with NF2 compared with those suffering from schwannomatosis, which could be explained by the fact that until recently we have not had a specialist neurootologist in our unit, and most patients with NF2 have presented with vestibular schwannomas to other units.
In our series, and as documented in the literature, FS, SS, and solitary schwannomas affected men and women equally. The average age at schwannomatosis onset was 28.3 years, whereas patients with solitary schwannomas are usually older, probably suggesting an important clinical discriminator between those entities. These findings are consistent with those in the series described by MacCollin et al., 17 in which more than onehalf of the patients became symptomatic in the second and third decades. A clinical and molecular study performed by Evans et at., 7 and more recently by Hadfield et al., 8 demonstrated the same results. However, Huang et al. 9 and Sappälä et al. 20 reported a mean age of 48.7 and 43.5 years, respectively, at the time of symptom onset in SS. Table 5 lists the demographic and clinical characteristics of the largest schwannomatosis case series published so far, including our own.
Thirteen of the 14 patients with schwannomatosis presented with pain as the first symptom, which was associated with spinal cord compression in 4 patients and the appearance of a mass in the other 10. Twelve patients had a benign course with no tumor recurrence after surgical intervention. One patient (Family 2) had a malignant schwannoma and died 31 months after diagnosis; a malignant schwannoma of an intercostal nerve was recently diagnosed in this patient's brother. This finding challenges the concept that schwannomatosis occurs only as benign tumors, 18 and we believe it is the first formal report of 2 malignant schwannomas in the same family in the context of FS. (Hadfield et al. 8 did mention a family member of 1 of their probands affected by a malignant peripheral nerve sheath tumor.) Eight (57%) of the 14 patients with schwannomatosis presented with at least 1 tumor in the spinal canal or attached to the spinal nerve roots. Similar findings in terms of location have been reported in all the case series published so far. In fact, the incidence of spinal tumors in the context of schwannomatosis ranges from 33% to 83%.
1,2,7,9,13,17,18,20 Interestingly, our series reveals that patients with FS had a spine compromised by schwannomas more frequently than those with SS, which was also noted by Evans et al. 7 and Hadfield et al. 8 (probably with some overlapping) as well as Jacoby et al. 12 These findings should be considered in patients with schwannomatosis by routine examination of the spine via MR imaging.
New symptomatic lesions developed in 4 patients during follow-up, as reported by Seppälä et al. 20 and MacCollin et al., 17 suggesting that schwannomatosis behaves like NF2 in that respect. One of these newly diagnosed schwannomas was malignant.
The molecular insights of the different forms of schwannomatosis are still unclear. In 1997 Jacoby et al. 12 found a mosaic alteration of the NF2 gene mutation. However, they also suggested a non-NF2 locus implicated in some patients. The CABIN1 gene, localized in the same chromosome 22 as NF2 but centromeric to it, has been implicated in the pathogenesis of both NF2 and schwannomatosis. 6 More recently, the role of the SMARCB1 tumor suppressor gene and its product, the INI1 protein, in both SS and FS has been supported by several reports. This gene is involved in about 50% of familial cases but in no more than 10% of the sporadic cases. Interestingly, the familial and sporadic forms of schwannomatosis also show different patterns of INI1 staining, making this test a potential tool for distinguishing between FS and SS until a more definite molecular diagnostic test becomes available. 5, 8, 10, 11, 13, 19, 21 Recently, the SMARCB1 has also been associated with the development of rhabdoid tumors and multiple meningiomas in families suffering from FS. 2, 5 No molecular testing was performed in any of our patients. The INI1/SMARCB1 tumor suppressor gene was at a very early stage in its clinical application to be indicated as a routine test when our study received approval (January 2008).
In the last 15 years there have been several clinical and molecular studies on schwannomatosis shedding more light on this new disease, and our findings are consistent with the results of most of them. Interestingly, in our cases schwannomatosis seemed to behave along a spectrum-some patients presented with very indolent forms, whereas others had malignant variations and died as a result of disseminated malignant tumors. This broad spectrum of behavior must be taken into account at the time of family counseling, especially if INI1/SMARCB1 becomes available for prenatal testing of the familial forms of schwannomatosis in the future.
In terms of follow-up imaging studies, we recommend routine whole-spine MR imaging in patients affected by schwannomatosis regardless of the location of the symptomatic tumor. At present, there is limited experience with this newly described disease, and the natural history of schwannomatosis in its varied forms is poorly understood, rendering it difficult to make strong recommendations in the long term. However, we know that schwannomatosis-related schwannomas tend to enlarge and also to grow in previously healthy nerves.
Given the ample variation in the behavior of schwannomatosis, the recommended interval between imaging studies should be dictated by the degree of the disease's aggressiveness in each individual. Patients with indolent forms of schwannomatosis would not require scans at short intervals, whereas those with the more aggressive forms would benefit from yearly imaging studies to diagnose new schwannomas or to follow up preexisting ones. Family history should be considered as well.
The indication for the excision of schwannomas in patients with schwannomatosis follows the same principles of the management of sporadic schwannomas. In our series, we surgically treated only symptomatic tumors or those demonstrating enlargement during the follow-up. This principle is shared by several authors who treat patients with schwannomatosis. 4, 9, 13, 22 
Conclusions
Patients suffering from schwannomatosis tend to be younger than those presenting with solitary schwannomas. Therefore, individuals presenting at a young age with multiple schwannomas but not meeting the criteria for NF2 should prompt the physician to suspect schwannomatosis.
The most common symptom on presentation in the current series was pain, and so patients with schwannomatosis and reporting pain should be exhaustively examined.
The spine is affected in the majority of patients with schwannomatosis, and MR imaging of the spine should be part of the routine evaluation.
The finding of 2 malignant schwannomas in patients with FS challenges the notion that schwannomatosis occurs only as benign tumors. Therefore, the rapid enlargement of schwannomas in the context of FS should cue suspicion of malignant transformation.
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